Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells.
breast cancer
dendritic cells
immune checkpoint molecules
radioresistance
radiotherapy
tumor cell death
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
06
2022
accepted:
28
03
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Only a subset of patients with triple-negative breast cancer (TNBC) benefits from a combination of radio- (RT) and immunotherapy. Therefore, we aimed to examine the impact of radioresistance and brain metastasizing potential on the immunological phenotype of TNBC cells following hypofractionated RT by analyzing cell death, immune checkpoint molecule (ICM) expression and activation of human monocyte-derived dendritic cells (DCs). MDA-MB-231 triple-negative breast cancer tumor cells were used as model system. Apoptosis was the dominant cell death form of brain metastasizing tumor cells, while Hsp70 release was generally significantly increased following RT and went along with necrosis induction. The ICMs PD-L1, PD-L2, HVEM, ICOS-L, CD137-L and OX40-L were found on the tumor cell surfaces and were significantly upregulated by RT with 5 x 5.2 Gy. Strikingly, the expression of immune suppressive ICMs was significantly higher on radioresistant clones compared to their respective non-radioresistant ones. Although hypofractionated RT led to significant cell death induction and release of Hsp70 in all tumor cell lines, human monocyte-derived DCs were not activated after co-incubation with RT-treated tumor cells. We conclude that radioresistance is a potent driver of immune suppressive ICM expression on the surface of TNBC MDA-MB-231 cells. This mechanism is generally known to predominantly influence the effector phase, rather than the priming phase, of anti-tumor immune responses.
Identifiants
pubmed: 37152024
doi: 10.3389/fonc.2023.981239
pmc: PMC10157086
doi:
Types de publication
Journal Article
Langues
eng
Pagination
981239Informations de copyright
Copyright © 2023 Gehre, Meyer, Sengedorj, Grottker, Reichardt, Alomo, Borgmann, Frey, Fietkau, Rückert and Gaipl.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
Front Immunol. 2016 Dec 22;7:610
pubmed: 28066420
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Cancer Immunol Res. 2020 Aug;8(8):1054-1063
pubmed: 32532811
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Cells. 2019 Aug 22;8(9):
pubmed: 31443516
Apoptosis. 2022 Dec;27(11-12):961-978
pubmed: 36018392
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Clin Exp Metastasis. 2015 Oct;32(7):717-27
pubmed: 26319493
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17456-61
pubmed: 21987811
JAMA Oncol. 2015 Oct;1(7):931-41
pubmed: 26247543
Front Immunol. 2022 Feb 25;13:765284
pubmed: 35280989
Lancet Oncol. 2019 Mar;20(3):e175-e186
pubmed: 30842061
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Mamm Genome. 2018 Dec;29(11-12):843-865
pubmed: 30178305
Front Oncol. 2021 Feb 25;10:600573
pubmed: 33718107
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Radiother Oncol. 2020 Jan;142:202-209
pubmed: 31767471
Strahlenther Onkol. 2021 Apr;197(4):269-280
pubmed: 33507331
Cancer. 2020 Feb 15;126(4):850-860
pubmed: 31747077
PLoS One. 2019 Dec 13;14(12):e0225898
pubmed: 31834886
Sci Rep. 2016 Jan 25;6:19740
pubmed: 26804478
Int J Mol Sci. 2018 Oct 29;19(11):
pubmed: 30380596
Radiat Oncol. 2015 Sep 17;10:197
pubmed: 26383236
Br J Cancer. 2003 Dec 15;89(12):2277-83
pubmed: 14676806
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Cancer Res. 2003 Nov 1;63(21):7462-7
pubmed: 14612546
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
Lancet. 2008 Mar 29;371(9618):1098-107
pubmed: 18355913
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572948
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
BMC Cancer. 2019 Mar 4;19(1):200
pubmed: 30832597
Arch Gynecol Obstet. 2016 Feb;293(2):247-69
pubmed: 26341644
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
Mol Oncol. 2020 Jul;14(7):1529-1537
pubmed: 32112478
Nat Struct Mol Biol. 2023 Mar;30(3):245-260
pubmed: 36894694
Radiat Oncol. 2014 Mar 30;9(1):89
pubmed: 24678590
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
Transl Oncol. 2020 Feb;13(2):410-422
pubmed: 31901781
Cancers (Basel). 2020 Apr 27;12(5):
pubmed: 32349284
Front Oncol. 2021 May 19;11:648139
pubmed: 34094935
Radiother Oncol. 2011 Oct;101(1):109-15
pubmed: 21704416
Int J Mol Sci. 2021 Aug 24;22(17):
pubmed: 34502022
Nat Protoc. 2021 Nov;16(11):4963-4991
pubmed: 34697469
Stem Cells. 2021 Sep;39(9):1155-1165
pubmed: 33961721
Semin Immunol. 2019 Jun;43:101299
pubmed: 31771762
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
Nature. 1997 Nov 27;390(6658):350-1
pubmed: 9389474
J Bone Miner Res. 2001 Aug;16(8):1486-95
pubmed: 11499871
Immunol Rev. 2017 Nov;280(1):231-248
pubmed: 29027224
Strahlenther Onkol. 2021 Dec;197(12):1043-1048
pubmed: 34515820
Front Immunol. 2021 Dec 14;12:797880
pubmed: 34970273
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Ann Surg Oncol. 2017 Dec;24(13):4042-4050
pubmed: 28612127
Front Oncol. 2020 Feb 20;10:164
pubmed: 32154167
Biomedicines. 2022 Mar 31;10(4):
pubmed: 35453571